AGENDA

1. Welcome and introduction
2. Apologies
3. Declarations of interest
4. Minutes of previous meeting
5. Chairman's report (verbal update)
6. All Wales Choose Pharmacy Formulary
7. Appraisal 1: Full Submission
   Beclometasone dipropionate/formoterol fumarate (Fostair®) for
   the symptomatic treatment of patients with COPD, with a FEV1 <
   50% predicted normal (pre-bronchodilator) and a history of repeated
   exacerbations, who have significant symptoms despite regular
   therapy with long-acting bronchodilators
8. Appraisal 2: Full Submission
   Brentuximab vedotin (Adcetris®) for the treatment of adult patients
   with relapsed or refractory CD30+ Hodgkin lymphoma following
   autologous stem cell transplant (ASCT) or following at least two prior
   therapies when ASCT or multi-agent chemotherapy is not a
   treatment option; as well as for the treatment of adult patients with
   relapsed or refractory systemic anaplastic large cell lymphoma
   (sALCL)
   For information
10. National Prescribing Indicators 2014–2015: Analysis of
    Prescribing Data to December 2014
    For information
11. All Wales Homecare Committee

Enclosure

1/AWMSG/0515
2/AWMSG/0515
3/AWMSG/0515
4/AWMSG/0515
5/AWMSG/0515
6/AWMSG/0515
7/AWMSG/0515
To protect commercial confidentiality the following 2 appraisals will be conducted in private as they include an associated patient access scheme

12. **Appraisal 3: Full Submission (WPAS)**
    Pomalidomide (Imnovid®) in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy

13. **Appraisal 4: Full Submission (PAS)**
    Enzalutamide (Xtandi®) for the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated

The meeting will open to the public for the announcement of AWMSG’s recommendations in relation to Appraisal 3 and 4

Date of next meeting: 17th June 2015 in Abergavenny